{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:23Z","timestamp":1786120343704,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01615-5","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:54:33Z","timestamp":1779123273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trametinib for multiple non-ossifying fibromas due to KRAS mosaic mutations: two case reports"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-5618","authenticated-orcid":false,"given":"Marie","family":"Vincent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soizic","family":"Tiriau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Fouillet-Desjonqueres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Ouchetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Barbarot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Isidor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymeric","family":"Rouchaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Baujat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vabres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Edery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Delous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5797-8152","authenticated-orcid":false,"given":"Massimiliano","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"1615_CR1","unstructured":"WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Soft-Tissue-And-Bone-Tumours-2020 (2020)."},{"key":"1615_CR2","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.3390\/jcm13195751","volume":"13","author":"E Berk","year":"2024","unstructured":"Berk, E. & Aydogan Baykara, R. Are fibrous cortical defects (FCDs) and non-ossifying fibromas (NOFs) only radiological findings? The relationship between radiological\/clinical findings and physical activity in children and adolescents: a cross-sectional study. J. Clin. Med. 13, 5751 (2024).","journal-title":"J. Clin. Med."},{"key":"1615_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/path.5216","volume":"248","author":"D Baumhoer","year":"2019","unstructured":"Baumhoer, D. et al. Activating mutations in the MAP-kinase pathway define non-ossifying fibroma of bone. J. Pathol. 248, 116\u2013122 (2019).","journal-title":"J. Pathol."},{"key":"1615_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies, M. A. et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 18, 863\u2013873 (2017).","journal-title":"Lancet Oncol."},{"key":"1615_CR5","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet, E. et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N. Engl. J. Med. 389, 1108\u20131120 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1615_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1161\/CIRCRESAHA.119.316500","volume":"127","author":"JE Fish","year":"2020","unstructured":"Fish, J. E. et al. Somatic gain of KRAS function in the endothelium is sufficient to cause vascular malformations that require MEK but not PI3K signaling. Circ. Res. 127, 727\u2013743 (2020).","journal-title":"Circ. Res."},{"key":"1615_CR7","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.3390\/jcm14186428","volume":"14","author":"K Walker","year":"2025","unstructured":"Walker, K., Smith, J. B., Todi, N., Brown, D. & Randall, R. L. Non-ossifying fibromas: a 2025 review. J. Clin. Med. 14, 6428 (2025).","journal-title":"J. Clin. Med."},{"key":"1615_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1056\/NEJMoa2309160","volume":"391","author":"A Fraissenon","year":"2024","unstructured":"Fraissenon, A. et al. Sotorasib for vascular malformations associated with KRAS G12C mutation. N. Engl. J. Med. 391, 334\u2013342 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1615_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15644\/asc56\/1\/9","volume":"56","author":"M Luna","year":"2022","unstructured":"Luna, M., Wolsefer, N., Zambrano, C. X. & Stojanov, I. J. Giant cell lesions of the jaws involving RASopathy syndromes. Acta Stomatol. Croat. 56, 77\u201388 (2022).","journal-title":"Acta Stomatol. Croat."},{"key":"1615_CR10","doi-asserted-by":"publisher","first-page":"bcr2017224115","DOI":"10.1136\/bcr-2017-224115","volume":"2018","author":"BP Sinnott","year":"2018","unstructured":"Sinnott, B. P. & Patel, M. Giant cell lesion of the jaw as a presenting feature of Noonan syndrome. BMJ Case Rep. 2018, bcr2017224115 (2018).","journal-title":"BMJ Case Rep."},{"key":"1615_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1590\/abd1806-4841.20164409","volume":"91","author":"DdeA Figueiras","year":"2016","unstructured":"Figueiras, D. deA. et al. Oculoectodermal syndrome: twentieth described case with new manifestations.  Bras. Dermatol. 91, 160\u2013162 (2016).","journal-title":"Bras. Dermatol"},{"key":"1615_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/13816810.2021.1998552","volume":"43","author":"M Kalavar","year":"2022","unstructured":"Kalavar, M., Echegaray, J. J., Ashkenazy, N., McKeown, C. & Berrocal, A. M. Choroidal calcifications in two cases of aplasia cutis congenita and oculoectodermal syndrome. Ophthalmic Genet. 43, 258\u2013261 (2022).","journal-title":"Ophthalmic Genet"},{"key":"1615_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ajmg.1320450620","volume":"45","author":"HV Toriello","year":"1993","unstructured":"Toriello, H. V., Lacassie, Y., Droste, P. & Higgins, J. V. Provisionally unique syndrome of ocular and ectodermal defects in two unrelated boys. Am. J. Med. Genet. 45, 764\u2013766 (1993).","journal-title":"Am. J. Med. Genet."},{"key":"1615_CR14","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/ajmg.a.37048","volume":"167","author":"JD Peacock","year":"2015","unstructured":"Peacock, J. D. et al. Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations. Am. J. Med. Genet. A 167, 1429\u20131435 (2015).","journal-title":"Am. J. Med. Genet. A"},{"key":"1615_CR15","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1111\/1346-8138.16440","volume":"49","author":"A Ververi","year":"2022","unstructured":"Ververi, A. et al. Patient with recurrent mosaic KRAS variant: Rare oculoectodermal syndrome with severe neurologic phenotype. J. Dermatol. 49, e381\u2013e382 (2022).","journal-title":"J. Dermatol."},{"key":"1615_CR16","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.3390\/ijms23074036","volume":"23","author":"A Beyens","year":"2022","unstructured":"Beyens, A. et al. Identification of codon 146 KRAS variants in isolated epidermal nevus and multiple lesions in oculoectodermal syndrome: confirmation of the phenotypic continuum of mosaic RASopathies. Int J. Mol. Sci. 23, 4036 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"1615_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00019605-199910000-00006","volume":"8","author":"HV Toriello","year":"1999","unstructured":"Toriello, H. V. et al. Non-ossifying fibromas and giant cell reparative granulomas in a child with ocular-ectodermal syndrome. Clin. Dysmorphol. 8, 265\u2013268 (1999).","journal-title":"Clin. Dysmorphol."},{"key":"1615_CR18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-3042","author":"RL Hollis","year":"2025","unstructured":"Hollis, R. L. et al. Molecular profiling and tumour biomarker analysis of GOG281\/LOGS: a positive late-phase trial of trametinib for recurrent\/persistent low grade-serous ovarian cancer. Clin. Cancer Res. J. Am. Assoc. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-3042 (2025).","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"1615_CR19","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/genes13091503","volume":"13","author":"M Lioncino","year":"2022","unstructured":"Lioncino, M. et al. Severe lymphatic disorder and multifocal atrial tachycardia treated with trametinib in a patient with Noonan syndrome and SOS1 mutation. Genes 13, 1503 (2022).","journal-title":"Genes"},{"key":"1615_CR20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-0167","volume":"146","author":"Y Dori","year":"2020","unstructured":"Dori, Y. et al. Severe lymphatic disorder resolved with MEK inhibition in a patient with Noonan syndrome and SOS1 mutation. Pediatrics 146, e20200167 (2020).","journal-title":"Pediatrics"},{"key":"1615_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.121.003327","volume":"14","author":"JK Meisner","year":"2021","unstructured":"Meisner, J. K., Bradley, D. J. & Russell, M. W. Molecular management of multifocal atrial tachycardia in Noonan\u2019s syndrome with MEK1\/2 inhibitor trametinib. Circ. Genom. Precis Med. 14, e003327 (2021).","journal-title":"Circ. Genom. Precis Med"},{"key":"1615_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/genes13010006","volume":"13","author":"A Mussa","year":"2021","unstructured":"Mussa, A. et al. MEK inhibition in a newborn with RAF1-associated Noonan syndrome ameliorates hypertrophic cardiomyopathy but is insufficient to revert pulmonary vascular disease. Genes 13, 6 (2021).","journal-title":"Genes"},{"key":"1615_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jpeds.2022.05.030","volume":"248","author":"TA Nakano","year":"2022","unstructured":"Nakano, T. A. et al. Trametinib for refractory chylous effusions and systemic complications in children with Noonan syndrome. J. Pediatr. 248, 81\u201388.e1 (2022).","journal-title":"J. Pediatr."},{"key":"1615_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytad190","volume":"7","author":"I Hribernik","year":"2023","unstructured":"Hribernik, I., Brooks, T., Dunlop-Jones, A. & Bentham, J. R. Successful treatment of refractory chylothorax with MEK inhibitor trametinib in a child with Noonan syndrome: case report. Eur. Heart J. Case Rep. 7, ytad190 (2023).","journal-title":"Eur. Heart J. Case Rep."},{"key":"1615_CR25","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.jacc.2019.01.066","volume":"73","author":"G Andelfinger","year":"2019","unstructured":"Andelfinger, G. et al. Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition. J. Am. Coll. Cardiol. 73, 2237\u20132239 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1615_CR26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/MPH.0000000000001170","volume":"40","author":"A Bavle","year":"2018","unstructured":"Bavle, A. et al. Encephalocraniocutaneous Lipomatosis. J. Pediatr. Hematol. Oncol. 40, 553\u2013554 (2018).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"1615_CR27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/gcc.23092","volume":"61","author":"D Carli","year":"2022","unstructured":"Carli, D. et al. Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome. Genes Chromosomes Cancer 61, 740\u2013746 (2022).","journal-title":"Genes Chromosomes Cancer"},{"key":"1615_CR28","first-page":"731","volume":"14","author":"A Gazzin","year":"2024","unstructured":"Gazzin, A. et al. Exploring new drug repurposing opportunities for MEK inhibitors in RASopathies: a comprehensive review of safety, efficacy, and future perspectives of trametinib and selumetinib. Life Basel Switz. 14, 731 (2024).","journal-title":"Life Basel Switz."},{"key":"1615_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","volume":"19","author":"WE Tidyman","year":"2009","unstructured":"Tidyman, W. E. & Rauen, K. A. The RASopathies: developmental syndromes of Ras\/MAPK pathway dysregulation. Curr. Opin. Genet. Dev. 19, 230\u2013236 (2009).","journal-title":"Curr. Opin. Genet. Dev."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01615-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01615-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01615-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T22:33:51Z","timestamp":1786055631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01615-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01615-5","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"432"}}